Association between urea trajectory and protein dose in critically ill adults: a secondary exploratory analysis of the effort protein trial (RE-EFFORT)

Haines, Ryan W.; Prowle, John R.; Day, Andrew; Bear, Danielle E.; Heyland, Daren K.; Puthucheary, Zudin

doi:10.1186/s13054-024-04799-1

Critical Care

Table 1 Baseline characteristics by urea trajectory group

From: Association between urea trajectory and protein dose in critically ill adults: a secondary exploratory analysis of the effort protein trial (RE-EFFORT)

	N	Low	Medium	High	All patients
		(N = 398)	(N = 568)	(N = 311)	(N = 1277)
Age, years	1277	35/49/61	50/61/71	54/63/70	46/59/69
Female	1276	44% 175/398	40% 226/568	35% 108/310	40% 509/1276
Randomised to high protein	1277	45% 178/398	47% 269/568	60% 186/311	50% 633/1277
Admission category:	1277	75% 297/398	86% 491/568	91% 284/311	84% 1072/1277
Medical	1277	75% 297/398	86% 491/568	91% 284/311	84% 1072/1277
Surgical Elective		5% 20/398	3% 19/568	1% 4/311	3% 43/1277
Surgical Emergency		20% 81/398	10% 58/568	7% 23/311	13% 162/1277
COVID-19 positive on admission	1277	2% 8/398	10% 55/568	6% 20/311	6% 83/1277
BMI	1277	21.6/24.8/29.8	23.5/26.9/34.2	22.1/26.4/32.3	22.5/26.0/32.2
Charlson Comorbidity Index	1277	0/0/1	0/0/1	0/1/2	0/0/1
Baseline SOFA score	1277	5/ 8/10	6/ 9/11	8/10/13	6/ 9/11
APACHE II score	1209	13.2/18.0/22.0	15.0/21.0/26.0	20.0/25.0/29.0	15/21/26
mNUTRIC score	1209	2/4/5	3/5/6	4/6/7	3/5/6
Frailty	1173	2/3/4	2/3/4	2/3/5	2/3/4
SARC-F score	1145	0/1/5	0/1/4	0/2/5	0/1/5
Renal replacement therapy on randomisation day	1277	3% 13/398	12% 70/568	43% 133/311	17% 216/1277
Acute kidney injury at time of randomisation*:	1277
Yes		9% 35/398	22% 124/568	47% 146/311	24% 305/1277
Stage 1		46% 16/35	48% 60/124	27% 40/146	38% 116/305
Stage 2		37% 13/35	25% 31/124	18% 27/146	23% 71/305
Stage 3		17% 6/35	27% 33/124	54% 79/146	39% 118/305
Moderate or severe chronic renal disease^$	1277	2% 7/398	6% 35/568	23% 70/311	9% 112/1277
ICU length of stay	1271	5.2/ 9.4/17.7	5.5/10.2/20.2	4.9/9.1/18.1	5.2/9.8/18.5
Hospital length of stay	1269	11.0/21.0/38.73	9.7/19.0/35.9	7.3/17.1/38.8	9.5/19.1/38.0
30-day mortality	1277	0.17 67/398	0.27 153/568	0.40 124/311	0.27 344/1277
60-day mortality	1277	0.22 88/398	0.33 185/568	0.47 147/311	0.33 420/1277

Bold value indicates median
a b c represent the lower quartile a, the median b, and the upper quartile c for continuous variables. Categorical variables are described by counts and percentages. N is the number of non-missing values. APACHE acute physiology and chronic health evaluation. ICU intensive care unit. SOFA sequential organ failure assessment. mNUTRIC modified nutrition risk assessment in critical illness score
*Acute kidney injury refers to patients who met the criteria of KDIGO: stage 1 is at least 26.52 μmol/L increase in serum creatinine from baseline within 48 h or 1.5–1.9 times baseline within 7 days; stage 2 is 2.0–2.9 times baseline within 7 days; stage 3 is three times or more baseline within 7 days or increase to at least 353.6 μmol/L with an acute increase of more than 44.2 μmol/L
^$Defined in comorbidities as moderate renal disease: creatinine clearance 51–85 mL/min; and severe renal disease: creatinine clearance less than 50 mL/min and not on dialysis

Back to article page

ISSN: 1364-8535

Contact us

Submission enquiries: journalsubmissions@springernature.com